Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia

Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma. Accor...

Descripción completa

Detalles Bibliográficos
Autores principales: Niswander, Lisa M., Graff, Zachary T., Chien, Christopher D., Chukinas, John A., Meadows, Christina A., Leach, Lillie C., Loftus, Joseph P., Kohler, M. Eric, Tasian, Sarah K., Fry, Terry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890025/
https://www.ncbi.nlm.nih.gov/pubmed/35950535
http://dx.doi.org/10.3324/haematol.2022.281456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890025/
https://www.ncbi.nlm.nih.gov/pubmed/35950535
http://dx.doi.org/10.3324/haematol.2022.281456

Ejemplares similares